
Unleashing the Power of CervoMed: Join Us for an Exciting Oral Presentation at the 8th International Lewy Body Dementia Conference!
CervoMed Inc. Announces Presentation of RewinD-LB Phase 2b Study Data at ILBDC Conference Topline Data Expected in December 2024 BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company specializing in treatments for age-related neurologic disorders, has disclosed that they will be sharing detailed safety and efficacy results from the completed…